News: GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,575.50GBp
17 Apr 2015
Change (% chg)

-20.50p (-1.28%)
Prev Close
1,596.00p
Open
1,586.00p
Day's High
1,604.00p
Day's Low
1,569.50p
Volume
10,129,879
Avg. Vol
8,579,234
52-wk High
1,689.00p
52-wk Low
1,296.50p

Search Stocks
Select another date:

Wed, Apr 1 2015

Firms' dispute over Avandia co-counsel fees headed to trial

- A federal judge on Tuesday ordered a trial to determine whether a Kansas law firm must arbitrate its claims against a California firm stemming from a fee-sharing agreement for litigation involving the diabetes drug Avandia.

J&J, Glaxo settle U.S. lawsuit over allergy ads

NEW YORK - GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson & Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share.

J&J, Glaxo settle U.S. lawsuit over allergy ads

NEW YORK - GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson & Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share.

J&J, Glaxo settle U.S. lawsuit over allergy ads

NEW YORK, March 30 - GlaxoSmithKline Plc has agreed to settle a lawsuit by Johnson & Johnson accusing it of using false advertising at the start of the U.S. allergy season to grab market share.

GSK agrees UK deal for meningitis shot after Novartis stand-off

LONDON - GlaxoSmithKline has reached a deal with the British government to supply a new meningitis B vaccine, following a lengthy stand-off over price with the product's previous owner Novartis.

GSK agrees UK deal for meningitis shot after Novartis stand-off

LONDON, March 29 - GlaxoSmithKline has reached a deal with the British government to supply a new meningitis B vaccine, following a lengthy stand-off over price with the product's previous owner Novartis.

BRIEF-GSK receives approval for Encruse Ellipta in Japan

* Press release - GSK receives approval for Encruse Ellipta (umeclidinium) in Japan for the treatment of COPD

UPDATE 2-FDA panel backs Glaxo asthma drug for adults, not adolescents

March 19 - GlaxoSmithKline Plc's drug to treat chronic breathing problems is safe and effective enough for adults with asthma to use but not adolescents, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

FDA staff finds no new safety problems with Glaxo's asthma drug

- GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems while being tested to treat asthma, a preliminary review by U.S. Food and Drug Administration staff found.

UPDATE 2-FDA staff finds no new safety problems with Glaxo's asthma drug

March 17 - GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems while being tested to treat asthma, a preliminary review by U.S. Food and Drug Administration staff found.

Select another date:
Search Stocks